Becton, Dickinson and Company

Valuation Analysis

About the Company

Becton, Dickinson and Company en bref

Becton, Dickinson and Company (BDX) is currently trading at 125,48 € with a market capitalization of 34,6 Md €. The trailing P/E ratio stands at 25.12x, with a forward P/E of 10.75x. The 52-week range spans from 111,23 € to 163,32 €; the current price is 23.2% below the yearly high. Year-over-year revenue growth stands at +5.2%. The net profit margin stands at 5.12%.

💰 Dividende

Becton, Dickinson and Company pays an annual dividend of 3,66 € per share, representing a yield of 2.92%. The payout ratio stands at 72.95%.

📊 Avis des analystes

13 analystes évaluent Becton, Dickinson and Company (BDX) au consensus : Acheter. L'objectif de cours moyen est de 157,52 €, soit un potentiel de +25.53% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 130,76 € à 196,15 €.

Becton, Dickinson and Company : la thèse d'investissement en détail

Becton, Dickinson and Company (BDX) operates in the Healthcare — specifically Medical Instruments & Supplies — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Wall Street consensus sits at Buy with an average price target implying roughly 25.53% upside from current levels — analyst sentiment is firmly constructive.

Valorisation en contexte

The PEG ratio at 1.11 sits in the reasonable zone — the price tag is roughly aligned with the company's growth profile, neither punishing nor euphoric. The EV/EBITDA multiple of 9.17x is below the historical equity-market average — strategic acquirers would find the cash-flow profile attractive at this level.

À surveiller

• The forward P/E of 10.75x is meaningfully below the trailing 25.12x — analysts expect earnings to step up; the next earnings release is the test.
• The analyst consensus price target implies 25.53% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Aperçu technique

Price is below both the 50- and 200-day moving averages, with 50d below 200d — a bearish picture (death-cross alignment).

Profil de risque

The data points to relatively defensive market behavior.

Trading Data

💵 Dividend Info

Related Stocks in the Same Sector

Where can I buy Becton, Dickinson and Company?

Compare top-rated brokers — low fees, trusted providers, fully regulated.